Nanexa enters EUR 1.165 billion global licensing deal with Novo Nordisk for long-acting injectables
Bitget2026/09/24 16:26- Nanexa entered a global exclusive license and collaboration agreement with Novo Nordisk for its PharmaShell drug-delivery platform.
- Deal targets long-acting injectable peptide drugs for obesity, type 2 diabetes, and other cardiometabolic indications.
- Novo secured rights for up to five development programs, aiming for monthly and quarterly dosing profiles.
- Nanexa is eligible for up to EUR 1.165 billion, including EUR 615 million in upfront and development and regulatory milestones.
- Agreement also includes sales milestones and low single-digit royalties on future product sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Microsoft Global Service Outage Investigation: A Vulnerability Lurking for Four Months, Problem Identified Only After 15 Hours
A vulnerability in Microsoft systems was triggered last week during a routine traffic switching operation. After a sudden surge in traffic, servers experienced memory exhaustion. The automated disaster recovery system then transferred the traffic to other "healthy" servers, but this inadvertently brought the vulnerability into these systems as well, causing a chain reaction of failures. It took about 15 hours from the initial occurrence of sporadic malfunctions to Microsoft's confirmation of the widespread issue. Microsoft then took another 15 hours before starting to roll out a fix, resulting in downtime much longer than similar incidents.

BUZZ-Cona Edison’s stock price drops due to planned stock issuance
BUZZ - Con Edison shares fall due to planned stock issuance
Celanese Elects Peter Matt to Board of Directors